Russell Thomas B, Ciprani Debora, Aroori Somaiah
Department of HPB Surgery, University Hospitals Plymouth NHS Trust, Plymouth, UK.
Ann Hepatobiliary Pancreat Surg. 2023 Nov 30;27(4):423-427. doi: 10.14701/ahbps.23-065. Epub 2023 Oct 17.
BACKGROUNDS/AIMS: Patients who undergo pancreatic surgery with venous resection have high rates of morbidity/mortality. Also, they are high-risk for postoperative venous thromboembolism. Whether this group should be routinely anticoagulated is unknown. This study aimed to establish current anticoagulation practices.
A survey (https://form.jotform.com/220242489107048) was sent out to pancreatic surgeons. Questions covered center volume, venous resection/reconstruction techniques and anticoagulation policies.
Sixty-five centers from 17 countries responded. Following a "side-bite" venous resection with a patch repair, 40% used an autologous vein patch, 27% used peritoneum, and 27% used a bovine patch. After formally resecting a segment of vein, 17% of centers used an interposition graft (IG). Left renal vein (41%) and polytetrafluoroethylene (73%) grafts were the most commonly used autologous and prosthetic IGs, respectively. Following a prosthetic IG, an autologous IG, and a "side-bite" resection, 59%, 28%, and 19% of centers provided therapeutic anticoagulation, respectively (66% used low molecular-weight heparin). The duration of therapy provided varied from inpatient stay only (14%) to six months (32%).
Our global survey indicates that anticoagulation practices are highly variable. Centers do not agree on when to anticoagulate, how to anticoagulate, or the duration of therapy. A robust trial is required to provide clarity.
背景/目的:接受胰腺手术并进行静脉切除的患者发病率/死亡率较高。此外,他们术后发生静脉血栓栓塞的风险也很高。该组患者是否应常规抗凝尚不清楚。本研究旨在确定当前的抗凝实践。
向胰腺外科医生发送了一项调查(https://form.jotform.com/220242489107048)。问题涵盖中心手术量、静脉切除/重建技术和抗凝政策。
来自17个国家的65个中心做出了回应。在采用补片修复的“侧咬式”静脉切除术后,40%的中心使用自体静脉补片,27%使用腹膜,27%使用牛心包补片。在正式切除一段静脉后,17%的中心使用了间置移植物(IG)。左肾静脉移植物(41%)和聚四氟乙烯移植物(73%)分别是最常用的自体和人工合成IG。在使用人工合成IG、自体IG和“侧咬式”切除术后,分别有59%、28%和19%的中心提供治疗性抗凝(66%使用低分子量肝素)。提供的治疗持续时间从仅住院期间(14%)到六个月(32%)不等。
我们的全球调查表明,抗凝实践差异很大。各中心在何时抗凝、如何抗凝或治疗持续时间上存在分歧。需要进行一项有力的试验来明确这些问题。